Comparative efficacy and safety among high-intensity statins. Systematic Review and Meta-Analysis
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To summarize the evidence in terms of efficacy and safety of head-to-head studies of high-intensity statins regardless of the underlying population. Materials & methods: A systematic review and meta-analysis was conducted to summarize the effect sizes in randomized controlled trials and cohort studies that compared high-intensity statins. Results: Based on 44 articles, similar effectiveness was observed across the statins in reducing LDL levels from baseline. All statins were observed to have similar adverse drug reactions (ADRs), although higher dosages were associated with more ADRs. Based on a pooled quantitative analysis of atorvastatin 80 mg versus rosuvastatin 40 mg, rosuvastatin was statistically more effective in reducing LDL. Conclusion: This review further confirms that high-intensity statins reduce LDL by ≥50%, favoring rosuvastatin over atorvastatin. Additional data are needed to confirm the clinical significance on cardiovascular outcomes using real-world studies.
Supplementary Material
File (supplementary materials.docx)
- Download
- 187.20 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
World Health Organization. Cardiovascular diseases (2021). Available from: www.who.int/health-topics/cardiovascular-diseases#tab=tab_1 (Accessed: 1 September 2022).
2.
Abushanab D, Al-Badriyeh D, Marquina C et al. A systematic review of cost-effectiveness of non-statin lipid-lowering drugs for primary and secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus. Curr. Probl. Cardiol. (2022).
3.
Talic S, Marquina C, Zomer E et al. Attainment of low-density lipoprotein cholesterol goals in statin treated patients: Real-world evidence from Australia. Curr. Probl. Cardiol. 47(7), 101068 (2022).
4.
Pedersen TR, Kjekshus J, Berg K et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934), 1383–1389 (1994).
5.
Long-Term Intervention with Pravastatin in Ischaemic Disease (Lipid) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339(19), 1349–1357 (1998).
6.
Amarenco P, Bogousslavsky J, Callahan A 3rd et al. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 355(6), 549–559 (2006).
7.
Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J. Am. Coll. Cardiol. 48(3), 438–445 (2006).
8.
Fulcher J, O'connell R, Voysey M et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385(9976), 1397–1405 (2015).
9.
Grundy SM, Stone NJ, Bailey AL et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 73(24), 3168–3209 (2019).
10.
Mills EJ, O'regan C, Eyawo O et al. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. Eur. Heart J. 32(11), 1409–1415 (2011).
11.
Cannon CP, Braunwald E, Mccabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350(15), 1495–1504 (2004).
12.
Larosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352(14), 1425–1435 (2005).
13.
Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 63(25 Pt B), 2889–2934 (2014).
14.
Rodriguez F, Lin S, Maron DJ, Knowles JW, Virani SS, Heidenreich PA. Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: practice impact of the new cholesterol guidelines. Am. Heart J. 182, 97–102 (2016).
15.
Pokharel Y, Tang F, Jones PG et al. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. JAMA Cardiol. 2(4), 361–369 (2017).
16.
Tran JN, Kao TC, Caglar T et al. Impact of the 2013 Cholesterol Guideline on Patterns of Lipid-Lowering Treatment in Patients with Atherosclerotic Cardiovascular Disease or Diabetes After 1 Year. J. Manag. Care Spec. Pharm. 22(8), 901–908 (2016).
17.
Giustino G, Colantonio LD, Brown TM et al. Titration to high-intensity statin therapy following acute myocardial infarction in patients with and without diabetes mellitus. Cardiovasc. Drugs Ther. 32(5), 453–461 (2018).
18.
National Institute for Health and Care Excellence. Lipid modifying drugs. Available from: www.nice.org.uk/guidance/ktt3 (2015 [updated 2019]).
19.
Meek CL, Reston JD, Ramsbottom T, Pathmanathan H, Viljoen A. Use of high-intensity statin therapy with simvastatin 80 mg and atorvastatin 80 mg in primary care. Int. J. Clin. Pract. 65(2), 120–126 (2011).
20.
Karlson BW, Wiklund O, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur. Heart J. Cardiovasc. Pharmacother. 2(4), 212–217 (2016).
•• Summarizes the extent of the variability in LDL-C reduction in response to treatment across the recommended doses of different statins regardless of intensity.
21.
Moorman JM, Boyle J, Bruno L et al. Utilization of high-intensity statins in patients at risk for cardiovascular events: a national cross-sectional study. Am. J. Ther. 29(1), e1–e17 (2020).
22.
Page MJ, Mckenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).
23.
Higgins JPT, Thomas J, Chandler Jet al. et al. (Eds). Cochrane Handbook for Systematic Reviews of Interventions. Version 6.2. Cochrane (2021). Available from: www.training.cochrane.org/handbook
24.
Crowe M, Sheppard L. A general critical appraisal tool: an evaluation of construct validity. Int. J. Nurs. Stud. 48(12), 1505–1516 (2011).
25.
Crowe M, Sheppard L, Campbell A. Reliability analysis for a proposed critical appraisal tool demonstrated value for diverse research designs. J. Clin. Epidemiol. 65(4), 375–383 (2012).
26.
Crowe M, Sheppard L, Campbell A. Comparison of the effects of using the Crowe Critical Appraisal Tool versus informal appraisal in assessing health research: a randomised trial. Int. J. Evid. Based Healthc. 9(4), 444–449 (2011).
27.
Review Manager (RevMan)[Computer program]. Version 5.4. The Cochrane Collaboration (2020). https://training.cochrane.org/online-learning/core-software/revman
28.
Rahhal A, Khir F, Aljundi AH et al. Clinical outcomes of high-intensity doses of atorvastatin in patients with acute coronary syndrome: a retrospective cohort study using real-world data. Br. J. Clin. Pharmacol. 87(4), 2043–2052 (2021).
29.
Betto M, Fares J, Saliba N, Ballout H. Efficacy and safety of a generic rosuvastatin in a real-world setting: prospective, observational clinical study in Lebanese patients. Ann. Saudi Med. 37(5), 366–374 (2017).
30.
Choi JY, Choi CU, Choi BG et al. New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins. BMC Pharmacol. Toxicol. 22(1), 11 (2021).
31.
Roy D, Mahapatra T, Manna K et al. Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: a non-concurrent cohort study in India. PloS One 15(5), e0233230–e0233230 (2020).
32.
Schneck DW, Knopp RH, Ballantyne CM, Mcpherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am. J. Cardiol. 91(1), 33–41 (2003).
33.
Leiter LA, Rosenson RS, Stein E et al. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 194(2), e154–e164 (2007).
34.
Ballantyne CM, Hoogeveen RC, Raya JL, Cain VA, Palmer MK, Karlson BW. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: results of the GRAVITY randomized study. Atherosclerosis 232(1), 86–93 (2014).
35.
Agrawal D, Manchanda SC, Sawhney JPS et al. To study the effect of high dose Atorvastatin 40 mg versus 80 mg in patients with dyslipidemia. Indian Heart J. 70(Suppl. 3), S8–S12 (2018).
36.
Aydin MU, Aygul N, Altunkeser BB, Unlu A, Taner A. Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction. Atherosclerosis 239(2), 439–443 (2015).
37.
De Zeeuw D, Anzalone DA, Cain VA et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 3(3), 181–190 (2015).
38.
Kilit C, Koçak FE, Paşalı Kilit T. Comparison of the effects of high-dose atorvastatin and high-dose rosuvastatin on oxidative stress in patients with acute myocardial infarction: a pilot study. Turk. Kardiyol. Dern. Ars. 45(3), 235–243 (2017).
39.
Jukema JW, Liem AH, Dunselman PH, Van Der Sloot JA, Lok DJ, Zwinderman AH. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Curr. Med. Res. Opin. 21(11), 1865–1874 (2005).
40.
Li Q, Zhao YG, Wang Z, Jiang HP, Liu WB, Cao BF. Effects of First High-Dose Atorvastatin Loading in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Am. J. Ther. 25(3), e291–e298 (2018).
41.
Crouse JR 3rd, Frohlich J, Ose L, Mercuri M, Tobert JA. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am. J. Cardiol. 83(10), 1476–1477 a1477 (1999).
42.
Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol. 92(11), 1287–1293 (2003).
43.
Mckenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr. Med. Res. Opin. 19(8), 689–698 (2003).
44.
Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 92(2), 152–160 (2003).
45.
Wolffenbuttel BH, Franken AA, Vincent HH. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes – CORALL study. J. Intern. Med. 257(6), 531–539 (2005).
46.
Stein B, Ward T, Hale G, Lyver E. Safety of High-Intensity Statins in the Veteran Population: atorvastatin 40 to 80 mg Compared With Rosuvastatin 20 to 40 mg. Ann. Pharmacother. 54(5), 405–413 (2020).
47.
Lablanche JM, Leone A, Merkely B et al. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study. Arch. Cardiovasc. Dis. 103(3), 160–169 (2010).
48.
Kaul U, Varma J, Kahali D et al. Post-marketing study of clinical experience of atorvastatin 80 mg vs 40 mg in Indian patients with acute coronary syndrome- a randomized, multi-centre study (CURE-ACS). J. Assoc. Physicians India 61(2), 97–101 (2013).
49.
Marais AD, Raal FJ, Stein EA et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis 197(1), 400–406 (2008).
50.
El Said NO, El Wakeel LM, Khorshid H, Darweesh EaG, Ahmed MA. Impact of lipophilic vs hydrophilic statins on the clinical outcome and biomarkers of remodelling in heart failure patients: a prospective comparative randomized study. Br. J. Clin. Pharmacol. 87(7), 2855–2866 (2021).
51.
Hoogerbrugge N, Jansen H. Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia. Atherosclerosis 146(1), 167–174 (1999).
52.
Toso A, Leoncini M, Maioli M, Tropeano F, Villani S, Bellandi F. A prospective, randomized, open-label trial of atorvastatin versus rosuvastatin in the prevention of contrast-induced acute kidney injury, worsened renal function at 30 days, and clinical events after acute coronary angiography: the PRATO-ACS-2 Study. Cardiorenal Med. 10(5), 288–301 (2020).
53.
Welty FK, Lewis SJ, Friday KE, Cain VA, Anzalone DA. A comparison of statin therapies in hypercholesterolemia in women: a subgroup analysis of the STELLAR Study. J. Womens Health (Larchmt) 25(1), 50–56 (2016).
54.
Pierri MD, Crescenzi G, Zingaro C et al. Prevention of atrial fibrillation and inflammatory response after on-pump coronary artery bypass using different statin dosages: a randomized, controlled trial. Gen. Thorac Cardiovasc. Surg. 64(7), 395–402 (2016).
55.
Sardella G, Lucisano L, Mancone M et al. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial. Int. J. Cardiol. 168(4), 3715–3720 (2013).
56.
Schwartz GG, Bolognese MA, Tremblay BP et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am. Heart J. 148(1), e4 (2004).
57.
Hong YJ, Jeong MH, Hachinohe D et al. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Circ. J. 75(2), 398–406 (2011).
58.
Khurana S, Gupta S, Bhalla H, Nandwani S, Gupta V. Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome. J. Pharmacol. Pharmacother. 6(3), 130–135 (2015).
59.
Illingworth DR, Crouse JR 3rd, Hunninghake DB et al. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr. Med. Res. Opin. 17(1), 43–50 (2001).
60.
Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). Am. J. Cardiol. 109(9), 1239–1246 (2012).
61.
Karalis DG, Ross AM, Vacari RM, Zarren H, Scott R. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am. J. Cardiol. 89(6), 667–671 (2002).
62.
Jacobs D, Wassell K, Guidry TJ, Sullivan J. Safety outcomes of atorvastatin 80 mg versus atorvastatin 40 mg in a veteran population. Ann. Pharmacother. 54(2), 151–156 (2020).
63.
Tunçez A, Altunkeser BB, Öztürk B et al. Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction. Anatol. J. Cardiol. 22(5), 240–249 (2019).
64.
Faergeman O, Hill L, Windler E et al. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology 111(4), 219–228 (2008).
65.
Bergheanu SC, Van Tol A, Dallinga-Thie GM et al. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Curr. Med. Res. Opin. 23(9), 2235–2240 (2007).
66.
Ballantyne CM, Blazing MA, Hunninghake DB et al. Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am. Heart J. 146(5), 862–869 (2003).
67.
Ciucanu CI, Olariu S, Vlad DC, Dumitraşcu V. Influence of rosuvastatin dose on total fatty acids and free fatty acids in plasma: correlations with lipids involved in cholesterol homeostasis. Medicine (Baltimore) 99(48), e23356 (2020).
68.
Altunkeser BB, Tuncez A, Ozturk B et al. Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome. Coron. Artery Dis. 30(4), 285–290 (2019).
69.
Thongtang N, Ai M, Otokozawa S et al. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am. J. Cardiol. 107(3), 387–392 (2011).
70.
Nicholls SJ, Ballantyne CM, Barter PJ et al. Effect of two intensive statin regimens on progression of coronary disease. N. Engl. J. Med. 365(22), 2078–2087 (2011).
71.
Jones PH, Mckenney JM, Karalis DG, Downey J. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am. Heart J. 149(1), e1 (2005).
72.
Kumar A, Shariff M, Doshi R. Impact of rosuvastatin versus atorvastatin on coronary atherosclerotic plaque volume - a systematic review and meta-analysis with trial sequential analysis of randomized control trials. Eur. J. Prev. Cardiol. 27(19), 2138–2141 (2020).
73.
Ma Q, Zhou Y, Zhai G et al. Meta-analysis comparing rosuvastatin and atorvastatin in reducing concentration of c-reactive protein in patients with hyperlipidemia. Angiology 67(6), 526–535 (2016).
• Article summarize the evidence of rosuvastatin vs atorvastatin showing better reducing of CRP with rosuvastatin
74.
Zhang L, Zhang S, Yu Y, Jiang H, Ge J. Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol: a meta-analysis of trials with East Asian populations. Herz 45(6), 594–602 (2020).
75.
Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140(11), e596–e646 (2019).
76.
Karlson BW, Nicholls SJ, Lundman P, Barter PJ, Palmer MK. Modeling statin-induced reductions of cardiovascular events in primary prevention: A VOYAGER Meta-Analysis. Cardiology 140(1), 30–34 (2018).
•• Summarizes the extent of the variability in LDL-C reduction in response to treatment across the recommended doses of different statins regardless of intensity.
77.
Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med. 342(25), 1887–1892 (2000).
78.
Boyko EJ. Observational research–opportunities and limitations. J. Diabetes Comp. 27(6), 642–648 (2013).
79.
Yetley EA, Demets DL, Harlan WR Jr. Surrogate disease markers as substitutes for chronic disease outcomes in studies of diet and chronic disease relations. Am. J. Clin. Nutrition 106(5), 1175–1189 (2017).
Information & Authors
Information
Published In
Copyright
© 2023 Becaris Publishing Limited.
History
Received: 8 September 2022
Accepted: 5 December 2022
Published online: 27 February 2023
Keywords:
Topics
Authors
Funding Information
Qatar University: QUST-1-CPH-2021-8
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Comparative efficacy and safety among high-intensity statins. Systematic Review and Meta-Analysis. (2023) Journal of Comparative Effectiveness Research. DOI: 10.57264/cer-2022-0163
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- A. P. Abramova, A. V. Sokolova, Iu. I. Poliakov, V. V. Kravtsova, V. M. Mikhailov, A. V. Kiselyov, M. G. Sokolova, The Effect of HMG-CoA Reductase Inhibitor on Muscle Endurance and Morphological State of Muscle Tissue in MDX Mice, Journal of Evolutionary Biochemistry and Physiology, 10.1134/S0022093026020043, 62, 2, (334-343), (2026).
- Wusa Makena, Monday Nwankwo, Aisha Idris, Onyinoyi Bethel Onimisi, Moses Sunday Adefisayo, Patrick Maduabuchi Aja, Ibe Michael Usman, Elna Owembabazi, Elizabeth Bassy Umoren, Ilemobayo Victor Fasogbon, Onyinye Vivian Ojiakor, Chinyere Nkemjika Anyanwu, Disparities in Low‐Birth‐Weight Prevalence Across Kenya: A Systematic Review and Meta‐Analysis of Maternal, Demographic, and Socioeconomic Risk Factors, Health Science Reports, 10.1002/hsr2.72404, 9, 4, (2026).
- Simona Chiusolo, Gabriele Masini, Viola Zywicki, Ida Rebecca Bort, Lucia Malloggi, Luna Gargani, Caterina Palagi, Raffaele De Caterina, High-intensity versus very-high-intensity statin, both on top of ezetimibe, in acute myocardial infarction: A pragmatic randomized study, International Journal of Cardiology, 10.1016/j.ijcard.2025.134140, 448, (134140), (2026).
- Amanda Rebonatto Oltramari, Alice Santos Da Silva, Marina Machado Cabrera, Geisson Marcos Nardi, Fátima Regina Mena Barreto Silva, Gabriel Adan Araújo Leite, Rosuvastatin exposure during adulthood increases ovarian follicular atresia and reduces reproductive performance in female mice, Toxicology Letters, 10.1016/j.toxlet.2026.111845, 417, (111845), (2026).
- Kun Yuan, Zi-tong Huang, Ri-lang Liu, Zi-wen Liu, Jie Lv, Can-can Li, Qian Xu, Major adverse events related to atorvastatin calcium hydrocarbons: pharmacovigilance study in the FAERS database, Canadian Journal of Physiology and Pharmacology, 10.1139/cjpp-2025-0288, 104, (1-15), (2026).
- Zhanna V. Filina, Marina I. Lityushkina, Zinaida G. Alayeva, Vadim O. Kiryukhin, Marina M. Dyrina, Analysis of Methods for Normalizing Lipid Profile and Blood Pressure in Patients with Chronic Coronary Syndromes, Medicine and Biotechnology, 10.15507/3034-6231.001.202503.286-297, 1, 3, (286-297), (2025).
- Muskaan Gupta, Ivica Smokovski, Dimitrios G. Chatzis, Kevin J. Spring, Man Mohan Mehndiratta, Roy G. Beran, Sonu M. M. Bhaskar, Statins in Acute Ischemic Stroke: Mechanisms, Resistance, and Precision Strategies for Neurovascular and Cognitive Protection, CNS Drugs, 10.1007/s40263-025-01222-3, 39, 11, (1083-1107), (2025).
- Mais N. Alqasrawi, Zeina N. Al-Mahayri, Lubna Q. Khasawneh, Areej S. AlBawa’neh, Lilas Dabaghie, Sahar M. Altoum, Dana Hamza, Salahdein Aburuz, Virendra Misra, Gohar Jamil, Husam Ouda, Faiz Al-Bakshy, Khuzama AlAhamad, Mohammad M. Al-Ahmad, Fatima Al-Maskari, Juma AlKaabi, George P. Patrinos, Bassam R. Ali, A multi-centre observational cohort study on pharmacogenomic predictors of rosuvastatin discontinuation in a multiethnic population, Frontiers in Pharmacology, 10.3389/fphar.2025.1656520, 16, (2025).
- Yiran Qin, Siyi Jin, Xusen Sun, Rong Luo, Haibo Liu, Effects of intensive rosuvastatin on ventricular remodeling and cardiac function in elderly patients with STEMI undergoing PCI, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2025.1638967, 12, (2025).
- Eva González-Iglesias, Jesús Novalbos, Francisco Abad-Santos, The pharmacogenetics of rosuvastatin and implications for treatment: a systematic review, Pharmacogenomics, 10.1080/14622416.2025.2547565, 26, 7-9, (311-329), (2025).
- See more